<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=undefined&type=result"></script>');
-->
</script>
Lipids can go through lipid peroxidation, an endogenous chain reaction that consists in the oxidative degradation of lipids leading to the generation of a wide variety of highly reactive carbonyl species (RCS), such as short-chain carbonyl derivatives and oxidized truncated phospholipids. RCS exert a wide range of biological effects due to their ability to interact and covalently bind to nucleophilic groups on other macromolecules, such as nucleic acids, phospholipids, and proteins, forming reversible and/or irreversible modifications and generating the so-called advanced lipoxidation end-products (ALEs). Lipoxidation plays a relevant role in the onset of cardiovascular diseases (CVD), mainly in the atherosclerosis-based diseases in which oxidized lipids and their adducts have been extensively characterized and associated with several processes responsible for the onset and development of atherosclerosis, such as endothelial dysfunction and inflammation. Herein we will review the current knowledge on the sources of lipids that undergo oxidation in the context of cardiovascular diseases, both from the bloodstream and tissues, and the methods for detection, characterization, and quantitation of their oxidative products and protein adducts. Moreover, lipoxidation and ALEs have been associated with many oxidative-based diseases, including CVD, not only as potential biomarkers but also as therapeutic targets. Indeed, several therapeutic strategies, acting at different levels of the ALEs cascade, have been proposed, essentially blocking ALEs formation, but also their catabolism or the resulting biological responses they induce. However, a deeper understanding of the mechanisms of formation and targets of ALEs could expand the available therapeutic strategies.
Glycation End Products, Advanced, Medicine (General), QH301-705.5, Lipoproteins, Lipid Metabolism, 4-Hydroxy-2-nonenal; Advanced lipoxidation end-products; Cardiovascular diseases; Lipoprotein; Lipoxidation; Mass spectrometry;, Oxidative Stress, R5-920, Lipoxidation in pathophysiology and its assessment by high precision methodology, Cardiovascular Diseases, Animals, Humans, Disease Susceptibility, Lipid Peroxidation, Biology (General), Oxidation-Reduction, Biomarkers
Glycation End Products, Advanced, Medicine (General), QH301-705.5, Lipoproteins, Lipid Metabolism, 4-Hydroxy-2-nonenal; Advanced lipoxidation end-products; Cardiovascular diseases; Lipoprotein; Lipoxidation; Mass spectrometry;, Oxidative Stress, R5-920, Lipoxidation in pathophysiology and its assessment by high precision methodology, Cardiovascular Diseases, Animals, Humans, Disease Susceptibility, Lipid Peroxidation, Biology (General), Oxidation-Reduction, Biomarkers
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 112 | |
popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 1% | |
influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 1% |